PCVX Key Statistics, Chart & Performance
The current stock price of PCVX is 45.84 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -46.26%.
PCVX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About PCVX
Company Profile
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 414 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Company Info
VAXCYTE INC
825 Industrial Road, Ste. 300
San Carlos CALIFORNIA 94404 US
CEO: Grant E. Pickering
Employees: 414
Phone: 16508370111
VAXCYTE INC / PCVX FAQ
Can you describe the business of VAXCYTE INC?
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 414 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
What is the current price of PCVX stock?
The current stock price of PCVX is 45.84 USD. The price decreased by -0.46% in the last trading session.
What is the dividend status of VAXCYTE INC?
PCVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of PCVX stock?
PCVX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting PCVX stock to perform?
16 analysts have analysed PCVX and the average price target is 99.96 USD. This implies a price increase of 118.06% is expected in the next year compared to the current price of 45.84.
How is the valuation of VAXCYTE INC (PCVX) based on its PE ratio?
VAXCYTE INC (PCVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.83).
PCVX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to PCVX. When comparing the yearly performance of all stocks, PCVX is a bad performer in the overall market: 85.27% of all stocks are doing better.
PCVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PCVX. No worries on liquidiy or solvency for PCVX as it has an excellent financial health rating, but there are worries on the profitability.
PCVX Financial Highlights
Over the last trailing twelve months PCVX reported a non-GAAP Earnings per Share(EPS) of -4.83. The EPS decreased by -5.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.72% | ||
| ROE | -22.72% | ||
| Debt/Equity | 0 |
PCVX Forecast & Estimates
16 analysts have analysed PCVX and the average price target is 99.96 USD. This implies a price increase of 118.06% is expected in the next year compared to the current price of 45.84.